Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder
Vistagen presented exploratory data at Psych Congress 2026 supporting fasedienol's potential in very severe social anxiety disorder (baseline LSAS of 95 or higher). Subpopulation analyses from PALISADE-4 Phase 3 and a Phase 2a repeat dose study showed statistically significant SUDS improvements versus placebo, with greater benefit after a second dose taken 10 minutes later; PALISADE-4 missed its primary endpoint in the total population.
Key figures
- Drug Name
- fasedienol nasal spray
- Phase Of Trial
- Phase 3 (PALISADE-4); Phase 2a repeat dose study
- Very severe lsas threshold
- 95
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.